March 4, 2019. We support the USPSTF’s draft recommendation against screening for pancreatic cancer in asymptomatic adults because screening asymptomatic adults does not improve patient outcomes and poses its own risks.
Read More »On Medical Treatments & Products
NCHR Testimony to FDA on Selinexor for Relapsed Refractory Multiple Myeloma
February 26, 2019. Selinexor has serious risks, and we don’t know if it works. Tell FDA to wait until the randomized trial is analyzed to make a decision.
Read More »Is FDA Doing Enough to Make Sure Sunscreens are Safe?
NCHR supports the FDA’s issued guidance regarding sunscreen sold over-the-counter that contains ingredients not thoroughly studied.
Read More »Statement on Behalf of Members of the Patient, Consumer, and Public Health Coalition at the FDA Advisory Committee on Vaginal Mesh
NCHR testified at the FDA regarding vaginal mesh and its harm on patients. Mesh went through a lax approval process and was not proven to be safe before use.
Read More »NCHR Testimony at FDA on Esketamine for Treatment Resistant Depression
February 12, 2019. The data from the clinical trials for esketamine nasal spray are encouraging, but there are still important questions concerning its safety and efficacy.
Read More »